Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 11, 2025
DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targetsPratik S Bhojnagarwala, Joshua Jose, Shushu Zhao, et al.Molecular Therapy Oncolytics|June 18, 2021
A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generationPratik S Bhojnagarwala, Alfredo Perales-Puchalt, Neil Cooch, et al.Cancer Immunology, Immunotherapy : CII|February 14, 2026
synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapyPratik S Bhojnagarwala, Devivasha Bordoloi, Joshua Jose, et al.Trends in Pharmacological Sciences|December 9, 2025
Siglecs in immunotherapy: current clinical landscape and prospectsAbhinav Purohit, Ishaan Joshi, Pratik S Bhojnagarwala, et al.Journal for Immunotherapy of Cancer|June 8, 2025
Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluationShushu Zhao, Yeqing Chen, Pratik S Bhojnagarwala, et al.Journal for Immunotherapy of Cancer|December 2, 2024
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cellsDaniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, et al.Molecular Therapy Oncolytics|September 12, 2022
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformePratik S Bhojnagarwala, Ryan P O'Connell, Daniel Park, et al.Journal for Immunotherapy of Cancer|June 4, 2024
Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinomaRyan P O'Connell, Kevin Liaw, Nils Wellhausen, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2026
Efficient in vivo assembly of DNA encoded multivalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancerPratik S Bhojnagarwala, Devivasha Bordoloi, Joshua S Jose, et al.JCI Insight|December 12, 2022
A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapyDevivasha Bordoloi, Pratik S Bhojnagarwala, Alfredo Perales-Puchalt, et al.Pageof 2